Emergency Allergy Shot: Epinephrine, Not Immunotherapy
An emergency allergy shot is NOT SCIT — it is epinephrine, the first-line rescue treatment for anaphylaxis. Current FDA-approved forms include EpiPen (1987), Auvi-Q (2012), and neffy nasal spray (August 9, 2024) — the first needle-free option. Epinephrine reverses acute anaphylaxis; it is single-use rescue only, not chronic or disease-modifying. SCIT and SLIT are the disease-modifying treatments — and every SCIT or SLIT patient should have epinephrine available as emergency backup.
6 peer-reviewed sources
An emergency allergy shot is intramuscular epinephrine — EpiPen, Auvi-Q, or neffy nasal spray (FDA-approved August 9, 2024). It is NOT subcutaneous allergen immunotherapy (SCIT). Epinephrine reverses anaphylaxis acutely; SCIT modifies the underlying allergy over 3–5 years.
The essentials
An emergency allergy shot is NOT SCIT — that disambiguation is the entire purpose of this page. Emergency allergy shot refers to intramuscular epinephrine delivered as an auto-injector or, since FDA approval on August 9, 2024, as a nasal spray.
Epinephrine is an alpha/beta-adrenergic agonist for 'emergency treatment of type I allergic reactions including anaphylaxis' — single-use rescue, explicitly NOT chronic, NOT preventive, and NOT disease-modifying. The three current FDA-approved epinephrine formulations are: EpiPen (first FDA-approved 1987; Teva generic approved 2018); Auvi-Q (voice-prompt auto-injector, FDA-approved 2012); and neffy (epinephrine nasal spray, ARS Pharmaceuticals, FDA-approved August 9, 2024, 2 mg dose) — described by the manufacturer as 'the first significant innovation in the delivery of epinephrine in more than 35 years' and 'the first and only needle-free' option. neffy pediatric 1 mg dose received FDA approval March 5, 2025.
Curex pairs at-home IgE testing with board-certified allergist review to identify the specific allergens driving a patient's reactions — the diagnostic foundation for both emergency epinephrine prescribing and any decision about long-term immunotherapy.
Per the World Allergy Organization, intramuscular epinephrine at 0.01 mg/kg of 1 mg/mL concentration (maximum 0.5 mg adult, 0.3 mg child) in the mid-anterolateral thigh is the universally recognized first-line treatment of anaphylaxis. Epinephrine reverses the systemic IgE-mediated mast-cell and basophil-driven cascade after it has occurred — it does not prevent it.
SCIT and SLIT are the disease-modifying treatments. A 3–5-year course of allergen immunotherapy per Cox L, Nelson H, Lockey R et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034) can reduce the likelihood and severity of future allergic reactions by inducing allergen-specific tolerance. But the SCIT patient still needs epinephrine available as emergency backup — Cox 2011 PP3 Summary Statements 33–36 state that 'the decision to prescribe epinephrine autoinjectors to patients receiving immunotherapy should be at the physician's discretion,' and FDA boxed warnings on all four SLIT tablets (Grastek, Oralair, Ragwitek, Odactra) require concurrent epinephrine auto-injector prescription.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
Epinephrine has no schedule — it is single-use rescue on an as-needed basis. The contrast with SCIT — which has a defined 3-phase scheduled timeline — is the central educational point of this page.
SCIT build-up involves 24–28 weekly visits escalating allergen dose per Cox 2011 PP3. Epinephrine is prescribed concurrently as emergency backup — not as part of the immunotherapy protocol. Every SCIT patient should have an epinephrine auto-injector available during build-up, when reaction risk is highest.
During SCIT maintenance, the allergist may continue the epinephrine auto-injector prescription per Cox 2011 PP3 at their clinical discretion. As allergen-specific tolerance increases through maintenance, the probability of a systemic reaction decreases — but does not reach zero. Epinephrine remains the first-line response to any systemic allergic event.
After completing SCIT, durable remission of 4+ years is documented by Durham SR et al., NEJM 1999;341:468–475. However, the need for epinephrine does not automatically end at SCIT discontinuation — patients with a history of anaphylaxis may be advised to carry epinephrine indefinitely by their allergist.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youSide effects — what to watch for
SCIT carries a defined spectrum of post-injection reactions ranging from local arm swelling to systemic anaphylaxis. Epinephrine is the emergency response when grade 3–4 systemic reactions occur during the mandatory 30-minute observation period.
Frequently asked questions
What is an emergency allergy shot?
An emergency allergy shot is intramuscular epinephrine — not allergen immunotherapy. Epinephrine is an alpha/beta-adrenergic agonist used for emergency treatment of type I IgE-mediated allergic reactions including anaphylaxis. Per the World Allergy Organization, the standard intramuscular dose is 0.01 mg/kg of 1 mg/mL concentration (maximum 0.5 mg for adults, 0.3 mg for children) administered into the mid-anterolateral thigh. Current FDA-approved epinephrine devices include EpiPen (1987), Auvi-Q (2012), and neffy nasal spray (August 9, 2024). Epinephrine is single-use rescue only — it reverses an acute anaphylaxis event but does not prevent future reactions or modify the underlying allergy.
Is an emergency allergy shot the same as an allergy shot for immunotherapy?
No — these are completely different categories. Subcutaneous allergen immunotherapy (SCIT) is a 3–5-year course of scheduled weekly (then monthly) injections of allergen extract designed to induce allergen-specific tolerance and modify the underlying immune response per Cox L et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034). An emergency allergy shot is epinephrine — a single-use rescue medication that reverses an acute anaphylaxis event in progress. They are complementary, not interchangeable: every SCIT or SLIT patient should have epinephrine available as emergency backup, but epinephrine does not replace or constitute immunotherapy.
What is neffy and how is it different from EpiPen?
neffy is epinephrine delivered as a nasal spray — the first needle-free epinephrine option. FDA approved neffy (ARS Pharmaceuticals) on August 9, 2024, for emergency treatment of type I allergic reactions including anaphylaxis in adults and pediatric patients aged 4 years and older weighing ≥15 kg. The manufacturer describes it as 'the first significant innovation in the delivery of epinephrine in more than 35 years.' A pediatric 1 mg dose received FDA approval on March 5, 2025. neffy offers the same indication and first-line treatment position as EpiPen and Auvi-Q, but eliminates the injection step — potentially addressing adherence barriers in needle-averse patients or situations where IM injection is difficult.
When should epinephrine be used for an allergic reaction?
Epinephrine is the first-line treatment for anaphylaxis. Per the World Allergy Organization, the diagnostic criteria for anaphylaxis include sudden onset of skin or mucosal symptoms (hives, flushing, lip swelling) AND at least one of: respiratory compromise, reduced blood pressure or associated symptoms, or severe gastrointestinal symptoms. Any combination of throat tightness, breathing difficulty, generalized hives, lightheadedness, nausea, or rapidly progressing symptoms in the context of a recent allergen exposure warrants immediate epinephrine. Call 911 regardless of whether epinephrine was administered — epinephrine has a brief duration of action and biphasic reactions can occur hours later. Do not delay epinephrine to take antihistamines first.
Should SCIT patients carry an epinephrine auto-injector?
Cox 2011 PP3 Summary Statements 33–36 state that 'the decision to prescribe epinephrine autoinjectors to patients receiving immunotherapy should be at the physician's discretion.' Many allergists prescribe epinephrine to SCIT patients as a precaution, particularly during build-up when systemic-reaction risk is highest. FDA boxed warnings on all four approved SLIT tablets (Grastek, Oralair, Ragwitek, Odactra) require a concurrent epinephrine auto-injector prescription with the first dose. For SCIT, the formal prescription is clinical-judgment-dependent, but carrying epinephrine represents the standard of care for patients with a history of systemic reactions to SCIT.
What is the difference between anaphylaxis from SCIT and a one-time emergency injection?
Anaphylaxis from SCIT is an adverse event — a grade 3–4 systemic reaction to an allergen injection during immunotherapy — managed with epinephrine and clinic emergency protocols during the mandatory 30-minute observation period per Cox 2011 PP3. An 'emergency allergy shot' in the context of a non-SCIT anaphylaxis event — from a food, bee sting, or medication — is epinephrine self-administered by the patient using an auto-injector outside the clinic. The medication (epinephrine) is the same; the clinical context differs. Per Epstein TG et al., Ann Allergy Asthma Immunol 2013 (PMID 23535092), one confirmed fatality occurred per 23.3 million SCIT injection visits during 2008–2012 — a safety record contingent on administration with epinephrine on hand.
Does epinephrine treat the same conditions as allergy shots?
Epinephrine and SCIT treat fundamentally different aspects of allergic disease. Epinephrine reverses an acute IgE-mediated mast-cell and basophil-driven anaphylaxis cascade — it does not address the underlying sensitivity. SCIT addresses the underlying sensitivity by inducing allergen-specific tolerance through IgG4 blocking antibody production, regulatory T-cell upregulation, and Th2 cytokine downregulation — but it does not rescue an acute event. SCIT may reduce the severity of future reactions (and may reduce the need for epinephrine use over time as tolerance builds), but even patients completing SCIT are not guaranteed to never experience a future allergic reaction requiring epinephrine.
Can a patient get allergy shots if they are on beta-blockers?
Beta-blocker use is a relative contraindication for SCIT per FDA allergen extract labeling, which states that 'patients receiving beta-blockers may not be responsive to epinephrine or inhaled bronchodilators.' This is clinically significant because if a systemic reaction occurs during SCIT, epinephrine — the first-line emergency response — may be less effective in patients on beta-blockers. Cox 2011 PP3 lists beta-blocker use as a factor to consider when evaluating SCIT candidacy. The decision is individualized — the allergist weighs the severity of the allergy and the clinical need for beta-blockers against the SCIT risk. Patients should inform their allergist of all medications including antihypertensives and cardiac medications before starting SCIT.
Related Articles
Types of Allergy Injections: Full Guide | Curex
Types of allergy injections include SCIT (immunotherapy), biologics like Xolair and Dupixent, depot steroids, and epinephrine. Only SCIT modifies the underlying disease.
Read moreCluster Allergy Shots: Schedule & Safety | Curex
Cluster allergy shots reach maintenance in 4–8 weeks vs 6 months. Schedule, the 3× higher per-injection reaction rate, and who qualifies (Tabar 2005).
Read moreYearly Allergy Shot: Kenalog vs. SCIT Explained | Curex
A 'yearly allergy shot' is either a depot steroid (Kenalog/Depo-Medrol — AAAAI discourages it) or pre-seasonal SCIT (rare US practice). Neither is disease modification over 3–5 years.
Read moreMonthly Allergy Shots: Maintenance Schedule Guide | Curex
SCIT maintenance shots — every 2-4 weeks for 3-5 years after build-up. Durham 1999 NEJM: 3 years yields 4 years of remission. Missed-dose rules inside.
Read moreCat Allergy Shots for Humans | Curex SCIT Guide
Cat allergy shots use FDA-standardized Fel d 1 extract for ~72% symptom relief. RCT evidence, schedule, plus at-home SCIT from Curex at $129/mo.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.